Supporting the

Neuroendocrine Cancer Community

Find a Clinical Trial 

Current Clinical Trials Recruiting in the UK

Click here to read about NCRI Badged clinical trials in the UK.

How to Find a Clinical Trial

Patients who want to volunteer for a clinical trial can search to find suitable studies in their geographic area. After finding a study on the website that looks like a good fit, the patient can contact the study investigators directly for more information on how to take part. This database is not the easiest to use and we are working with the iCancer team and INCA to find a easier solution to engaging more patients in clinical trials and to make the information about that trial easier.

Below is a step by step guide that we found on the Ipsen website.

1. Find the clinical trials website which is the world’s biggest database of studies that are looking for participants.

2. In the “Search for Studies” box, type in your diagnosis (for example Neuroendocrine tumour) and hit Search – this narrows the search that might be relevant to you. If you can’t find any studies on your condition, try expanding you’re your search using “OR” – for example, Neuroendocrine tumour OR neoplasm. You also have the option of going to the “Find Studies” tab and choosing “Advanced Search” – this lets you enter all your search information at once. With this option, you can enter specific locations, but you may miss clinical trials that are close to that area.

3. Above the checklist, check the box beside “Only show open studies” – this eliminates the studies that have finished finding volunteers.

4. Click on the blue tab that says “On Map” – this helps you find a clinical trial close to where you live, or in another specific place. Then scroll down to “Region Name”. Click on the word “map” beside your region (either continent or country). You might get another region list, allowing you to click on a more specific region.

5. Besides your chosen region, click on “studies” – this will give you the list of studies in your specific region.

6. Look at the list of studies, paying attention to the information besides “Condition” and “Intervention”. The condition should match your diagnosis, and intervention should match the kind of treatment you might try. Click on the title of a study that looks like a good fit – this gives you the details of a relevant clinical trial. “Interventional” studies focus on delivering a therapy in a controlled way. “Observational” studies might not list and intervention since they track health in natural settings for large groups of people.

7. Once you find a study that interests you, read through the information and make sure the points under “Eligibility” apply to you, because everyone who joins the study must meet these criteria. If you’re not sure, schedule a time to talk to your doctor about it (If any of the points under “Exclusion Criteria” are true for you, look for a different study.

8. If you meet all the criteria under “Eligibility”, it might be the right study for you. Find the phone number or email address under “Contacts and Locations” and inquire for more information – this puts you in touch with the study investigators but does not commit you to joining the study.

COMPETE study Recruiting Now

January 2021

The COMPETE trial is a Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET).

Below are the current COMPETE hospitals in your country:
Beatson Oncology Centre, Gartnavel General Hospital
Not yet recruiting
Glasgow, United Kingdom, G12 0YN

Royal Free NHS Foundation Trust
London, United Kingdom, NW3 2QG

Kings College Hospital
London, United Kingdom, SE5 9RS

This list is regularly updated in

Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide

February 2021

This phase II trial studies the effect of lutetium Lu 177 dotatate in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Radioactive drugs, such as lutetium Lu 177 dotatate, may carry radiation directly to tumor cells and not harm normal cells. Giving lutetium Lu 177 dotatate instead of standard of care everolimus may lower the chances of neuroendocrine tumors growing or spreading.

Chief Investigator: Thomas A Hope

NET-02 Study Recruiting Now

February 2020

NET-02: A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (NEC).

Chief Investigator: Dr Mairéad McNamara

aRTisAN Study Recruiting Now

November 2020

aRTisAN: A Phase II Assessment of the Safety and Efficacy of TheraSphere® Selective Internal Radiation Therapy (SIRT) in the treatment of Metastatic (Liver) Neuroendocrine Tumours (NETs).

Chief Investigator:Dr Rohini Sharma, Imperial College London

Find Trials Around The World

The Only Crowd-Funded Cancer Drug Trial in History

In 2018 the team at Uppsala University  prepared this video update on the AdVince phase 1 clinical trial for neuroendocrine tumour.

“A total of twelve patients will have to be treated at different dose levels. So far five patients have been treated and there are still seven patients to go, ” says Prof Magnus Essand.

“The first patient was treated in March 2016 so we hope that we can now finish the next seven in the next two years from now.

“Phase1 trial is about safety data primarily, that is the primary endpoint. But of course, we are also looking at efficacy if there are response.

“And we have seen responses already at the lower dosages we have seen occasions of tumour shrinkage in the liver that has been treated.

“So it is promising but before we say anything conclusive we need to finish the phase1 trial and we need to treat even more patients before we can make any firm conclusions. So it is very early days.”


Further information about AdVince can be found here.


Trying to find the best investigation to get the most relevant information about what is happening to your Neuroendocrine Cancer is really important, so that the right diagnostic, treatment and follow up plans can be made.

‘NETest’ is a potentially new way of assessing and monitoring Neuroendocrine Cancer  through a blood test.

Research is always moving forward to find potentially new. more specific and less invasive tests that can be used to let your specialist team know what the activity of your Neuroendocrine Cancer.

The NETest is a blood test and may provide this information.

Whilst there are no formal clinical trials into the NETest in the UK at this time (2020), there are several ENETS Centres of Excellence that are using free-of-charge samples of the NETest, as part of their routine follow-up of NET patients – to assess its efficacy and accuracy.

***Please note the information above is commercial information provided by an external source and not from Neuroendocrine Cancer UK.**

Our Published Research

Research undertaken by Neuroendocrine Cancer UK  – in-house and in partnership with clinical experts.

Completed Studies

Click here for a list of recently published trials that may be of interest to you. 

About Us

Neuroendocrine Cancer UK is a UK wide charity solely dedicated to providing support and information to those affected by Neuroendocrine Cancer.


Subscribe to our Newsletter to stay update with our latest news.


Holly House, 74 Upper Holly Walk, Leamington Spa CV32 4JL